363 related articles for article (PubMed ID: 11497250)
61. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
62. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
[TBL] [Abstract][Full Text] [Related]
63. [Nedaplatin (NDP)-combination therapy (NDP/5-FU,NDP/S-1) for oral cancer].
Maruoka Y; Ando T; Ogiuchi Y; Ogiuchi H
Gan To Kagaku Ryoho; 2007 May; 34(5):713-7. PubMed ID: 17496443
[TBL] [Abstract][Full Text] [Related]
64. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Oshima T; Yamada R; Hatori S; Kunisaki C; Imada T
Oncol Rep; 2006 Aug; 16(2):361-6. PubMed ID: 16820916
[TBL] [Abstract][Full Text] [Related]
65. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
Kochi M; Fujii M; Kanamori N; Kaiga T; Aizaki K; Takahashi T; Takayama T
Cancer Chemother Pharmacol; 2007 Oct; 60(5):693-701. PubMed ID: 17690883
[TBL] [Abstract][Full Text] [Related]
66. Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma.
Nakazawa M; Ohnishi T; Ohmae M; Chisoku H; Yui S; Iwai S; Sumi T; Fukuda Y; Kishino M; Yura Y
Int J Clin Pharmacol Res; 2005; 25(3):115-22. PubMed ID: 16366419
[TBL] [Abstract][Full Text] [Related]
67. Antitumor effect of S-1 on DMH induced colon cancer in rats.
Tsunoda A; Shibusawa M; Tsunoda Y; Yokoyama N; Nakao K; Kusano M; Nomura N; Nagayama S; Takechi T
Anticancer Res; 1998; 18(2A):1137-41. PubMed ID: 9615778
[TBL] [Abstract][Full Text] [Related]
68. Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.
Ooyama A; Oka T; Zhao HY; Yamamoto M; Akiyama S; Fukushima M
Cancer Lett; 2008 Aug; 267(1):26-36. PubMed ID: 18420342
[TBL] [Abstract][Full Text] [Related]
69. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
Nakata E; Fukushima M; Takai Y; Nemoto K; Ogawa Y; Nomiya T; Nakamura Y; Milas L; Yamada S
Oncol Rep; 2006 Sep; 16(3):465-71. PubMed ID: 16865244
[TBL] [Abstract][Full Text] [Related]
70. [Development of fluorinated pyrimidines in Japan].
Taguchi T
Gan To Kagaku Ryoho; 1993 Jan; 20(1):10-8. PubMed ID: 8422172
[TBL] [Abstract][Full Text] [Related]
71. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
[TBL] [Abstract][Full Text] [Related]
72. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells.
Harada K; Kawaguchi S; Supriatno ; Onoue T; Yoshida H; Sato M
Oral Oncol; 2004 Aug; 40(7):713-9. PubMed ID: 15172641
[TBL] [Abstract][Full Text] [Related]
73. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.
Sakata Y; Ohtsu A; Horikoshi N; Sugimachi K; Mitachi Y; Taguchi T
Eur J Cancer; 1998 Oct; 34(11):1715-20. PubMed ID: 9893658
[TBL] [Abstract][Full Text] [Related]
74. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
75. Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.
Mori T; Fujiwara Y; Yano M; Tamura S; Yasuda T; Takiguchi S; Monden M
Oncology; 2003; 64(2):176-82. PubMed ID: 12566916
[TBL] [Abstract][Full Text] [Related]
76. Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.
Baba E; Fujishima H; Kusaba H; Esaki T; Ariyama H; Kato K; Tanaka R; Mitsugi K; Shibata Y; Harada M; Nakano S
Anticancer Res; 2009 May; 29(5):1727-32. PubMed ID: 19443394
[TBL] [Abstract][Full Text] [Related]
77. [Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (I)--Fertility study in rats by oral administration].
Shinomiya M; Imamura K; Izumi K
J Toxicol Sci; 1996 Nov; 21 Suppl 3():589-602. PubMed ID: 9021663
[TBL] [Abstract][Full Text] [Related]
78. [Combined effect of S-1 and CDDP as a modulator for colon 26 liver metastasis].
Kitamura M; Arai K; Iwasaki Y; Takahashi T; Saitoh K; Fujii T; Shirasaka T
Gan To Kagaku Ryoho; 2000 Apr; 27(4):559-63. PubMed ID: 10790998
[TBL] [Abstract][Full Text] [Related]
79. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Nishiyama T; Ogura K; Nagayama S; Ikeda K; Yamaguchi S; Nakamura Y; Kawaguchi K; Watabe T; Ogura Y
Drug Metab Dispos; 1997 Feb; 25(2):270-3. PubMed ID: 9029059
[TBL] [Abstract][Full Text] [Related]
80. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
